MacroGenics Company Profile (NASDAQ:MGNX)

About MacroGenics

MacroGenics logoMacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MGNX
  • CUSIP:
Key Metrics:
  • Previous Close: $30.00
  • 50 Day Moving Average: $29.63
  • 200 Day Moving Average: $22.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.81
  • P/E Growth: 0.08
  • Market Cap: $1.04B
  • Outstanding Shares: 34,733,000
  • Beta: 2.81
Additional Links:
Companies Related to MacroGenics:

Analyst Ratings

Consensus Ratings for MacroGenics (NASDAQ:MGNX) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $38.71 (29.05% upside)

Analysts' Ratings History for MacroGenics (NASDAQ:MGNX)
DateFirmActionRatingPrice TargetDetails
8/4/2016Citigroup Inc.DowngradeBuy -> Neutral$27.00 -> $32.00View Rating Details
6/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/14/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
5/22/2016BTIG ResearchReiterated RatingBuy$35.00View Rating Details
5/19/2016Leerink SwannReiterated RatingOutperform$47.00View Rating Details
5/18/2016WedbushReiterated RatingOutperform$52.00View Rating Details
2/18/2016Janney Montgomery ScottInitiated CoverageBuy$36.00View Rating Details
10/5/2015Roth CapitalReiterated RatingBuyView Rating Details
8/6/2015Stifel NicolausReiterated RatingBuy$51.00 -> $56.00View Rating Details
(Data available from 8/27/2014 forward)


Earnings History for MacroGenics (NASDAQ:MGNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)ViewN/AView Earnings Details
2/29/2016Q4($0.60)($0.88)ViewListenView Earnings Details
8/3/2015Q2($0.44)($0.71)ViewN/AView Earnings Details
5/6/2015$0.87($0.58)ViewN/AView Earnings Details
3/3/2015($0.36)($0.69)ViewN/AView Earnings Details
11/11/2014($0.42)($0.14)ViewListenView Earnings Details
8/5/2014($0.29)($0.44)ViewN/AView Earnings Details
5/6/2014($0.09)($0.12)ViewN/AView Earnings Details
11/12/2013$0.15$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MacroGenics (NASDAQ:MGNX)
Current Year EPS Consensus Estimate: $-1.15 EPS
Next Year EPS Consensus Estimate: $-3.84 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.92)($0.46)($0.70)
Q2 20164($0.91)($0.48)($0.69)
Q3 20163($0.92)($0.77)($0.84)
Q4 20163($1.02)($0.81)($0.94)
Q1 20171($0.85)($0.85)($0.85)
Q2 20171($0.88)($0.88)($0.88)
Q3 20171($0.90)($0.90)($0.90)
Q4 20171($0.92)($0.92)($0.92)
(Data provided by Zacks Investment Research)


Dividend History for MacroGenics (NASDAQ:MGNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for MacroGenics (NASDAQ:MGNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.00View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.00View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.84View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.00View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.00View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.00View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.48View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.93View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for MacroGenics (NASDAQ:MGNX)
DateHeadline logoAnalysts See MacroGenics, Inc. (NASDAQ:MGNX) Reporting EPS Of $-0.9 - (NASDAQ:MGNX) - August 20 at 5:55 PM logoProMetic reports second quarter 2016 highlights and financial results (NASDAQ:MGNX) - August 11 at 6:34 PM logoMACROGENICS INC Financials (NASDAQ:MGNX) - August 10 at 6:36 PM logoETF’s with exposure to MacroGenics, Inc. : August 8, 2016 (NASDAQ:MGNX) - August 8 at 6:22 PM logoMacroGenics, Inc. :MGNX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:MGNX) - August 5 at 6:21 PM logoMacroGenics downgraded by Citigroup (NASDAQ:MGNX) - August 4 at 6:30 PM logoMacroGenics to Participate in Two Upcoming Investor Conferences (NASDAQ:MGNX) - August 4 at 9:18 AM logoMacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results (NASDAQ:MGNX) - August 3 at 6:30 PM logoMacroGenics beats Street 2Q forecasts (NASDAQ:MGNX) - August 3 at 6:30 PM logoQ2 2016 MacroGenics Inc Earnings Release - After Market Close (NASDAQ:MGNX) - August 3 at 9:27 AM logoEarnings Surprise in Focus: MacroGenics, Inc. (NASDAQ:MGNX) - Investor Newswire (NASDAQ:MGNX) - July 31 at 5:45 PM logoMacroGenics, Inc. (MGNX) - Financial and Strategic SWOT Analysis Review - New Market Research Report (NASDAQ:MGNX) - July 28 at 6:23 PM logoMacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call (NASDAQ:MGNX) - July 27 at 4:48 PM logoWill MacroGenics, Inc. (NASDAQ:MGNX) Surprise This Quarter? - Investor Newswire (NASDAQ:MGNX) - July 26 at 6:29 PM logoMacroGenics Inc (NASDAQ:MGNX) Upside Stock Technicals at Extreme Strength - CML News (NASDAQ:MGNX) - July 23 at 10:06 AM
News IconAre Analysts Bearish MacroGenics Inc (NASDAQ:MGNX) After Last Week? - Consumer Eagle (NASDAQ:MGNX) - July 22 at 9:08 AM logoMacroGenics Inc. (MGNX) Jumps 6.43% on July 20 - (NASDAQ:MGNX) - July 22 at 9:08 AM
News IconHeightened Volatility Spotted on Shares of: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily (NASDAQ:MGNX) - July 19 at 11:50 AM
News IconStock in Positive Territory for the Quarter: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily (NASDAQ:MGNX) - July 19 at 11:50 AM
News IconShare Performance Summary for: MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph (NASDAQ:MGNX) - July 18 at 11:29 AM logoMacroGenics, Inc. (NASDAQ:MGNX) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:MGNX) - July 17 at 5:40 PM
News IconCrowd Rating and Earnings Recap for MacroGenics, Inc. (NASDAQ:MGNX) - Telanagana Press (NASDAQ:MGNX) - July 15 at 10:37 AM
News IconMacroGenics, Inc. (NASDAQ:MGNX) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:MGNX) - July 14 at 6:27 PM
News IconHow Analysts Rated MacroGenics Inc (NASDAQ:MGNX) Last Week? - Consumer Eagle (NASDAQ:MGNX) - July 14 at 6:27 PM
News IconMacroGenics, Inc. (NASDAQ:MGNX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:MGNX) - July 12 at 10:34 AM
News IconTrading Performance and Target Watch for MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph (NASDAQ:MGNX) - July 12 at 10:34 AM logoTraders Are Watching: MacroGenics, Inc. (NASDAQ:MGNX), Cymabay Therapeutics, Inc. (NASDAQ:CBAY), Biogen Inc ... - KC Register (NASDAQ:MGNX) - July 11 at 10:49 AM
News IconStock on the Rise for the Quarter: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily (NASDAQ:MGNX) - July 11 at 10:49 AM logoNext Weeks Broker Price Targets For MacroGenics, Inc. (NASDAQ:MGNX) - Fiscal Standard (NASDAQ:MGNX) - July 11 at 10:49 AM
News IconStock Performance Rundown on: MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph (NASDAQ:MGNX) - July 11 at 10:49 AM
News IconWall Street Ratings and Target Price Views on MacroGenics, Inc. (NASDAQ:MGNX) - Telanagana Press (NASDAQ:MGNX) - July 8 at 9:03 AM
News IconMacroGenics, Inc. (NASDAQ:MGNX) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:MGNX) - July 7 at 6:12 PM logoNew Broker Ratings For MacroGenics, Inc. (NASDAQ:MGNX) - FTSE News (NASDAQ:MGNX) - July 6 at 10:48 AM
News IconStock Tracking Down This Month; Investor Alert on MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily (NASDAQ:MGNX) - July 6 at 10:48 AM
News IconStock Rating Watch and Earnings Insight for MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph (NASDAQ:MGNX) - July 6 at 10:48 AM
News IconShare Performance Recap for: MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph (NASDAQ:MGNX) - July 4 at 5:36 PM
News IconShare Update and Earnings Review for MacroGenics, Inc. (NASDAQ:MGNX) - Press Telegraph (NASDAQ:MGNX) - June 30 at 6:30 PM
News IconMacroGenics, Inc. (NASDAQ:MGNX) Company Rating and Target Watch - Telanagana Press (NASDAQ:MGNX) - June 30 at 6:30 PM
News IconHow Analysts Feel About MacroGenics Inc (NASDAQ:MGNX)? - Engelwood Daily (NASDAQ:MGNX) - June 30 at 6:30 PM
News IconMacrogenics Incorporated (NASDAQ:MGNX) Sellers Increased By 1.33% Their Shorts - Engelwood Daily (NASDAQ:MGNX) - June 28 at 6:02 PM
News IconCheck on Share Volatility: MacroGenics, Inc. (NASDAQ:MGNX) - Engelwood Daily (NASDAQ:MGNX) - June 28 at 6:02 PM
News IconMacroGenics Inc (NASDAQ:MGNX)'s Company Shares Decreased 5.92% After High Volatility - Press Telegraph (NASDAQ:MGNX) - June 28 at 6:02 PM logoMacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015 (NASDAQ:MGNX) - June 28 at 7:30 AM logoMacroGenics Inc. (MGNX) Jumps 8.2% on June 23 - (NASDAQ:MGNX) - June 25 at 5:47 PM logoRecently Issued Stock Ratings For MacroGenics, Inc. (NASDAQ:MGNX) - Fiscal Standard (NASDAQ:MGNX) - June 22 at 10:52 AM logoMacroGenics, Inc. (NASDAQ:MGNX) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:MGNX) - June 20 at 6:31 AM
News IconAnalysts Have Conflicting Sentiments on These Healthcare Companies: MacroGenics Inc (NASDAQ: MGNX), Seattle ... - Analyst Ratings (NASDAQ:MGNX) - June 14 at 5:55 PM logoMacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology (EULAR 2016) (NASDAQ:MGNX) - June 10 at 6:09 AM logoMacroGenics Inc. (MGNX) Jumps 6.9% on June 06 - (NASDAQ:MGNX) - June 7 at 6:21 PM
News IconPerformance Review for MacroGenics, Inc. (NASDAQ:MGNX) - HNN (NASDAQ:MGNX) - June 6 at 9:51 AM


MacroGenics (NASDAQ:MGNX) Chart for Saturday, August, 27, 2016

Last Updated on 8/27/2016 by Staff